Clinical trial
Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer
NCT00411229 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00411229 |
|---|---|
| Title | Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer |
| Official title | A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin vs Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4NO), and IIIb (T3N2) Gastric Adenocarcinoma |
| Acronym | CLASSIC |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Stomach Neoplasms |
| Intervention type | Drug |
| Interventions | Capecitabine, Oxaliplatin |
| Enrollment | 1,035 |
| Start date | Jun 1, 2006 |
| Primary completion | Nov 1, 2012 |
| Completion | Nov 1, 2012 |
| First posted | Dec 13, 2006 |
| Last update posted | Feb 20, 2013 |
| Countries | China, South Korea, Taiwan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: